In this regard, it should be noted that the first large-scale GLP-1 cardiovascular trials recently reported that the DPP-4 inhibitors, saxagliptin and alogliptin, did not confer cardiovascular benefit in type 2 diabetes [61, 62], although there are currently no data from long-term randomised clinical trials with GLP-1R agonists, with several ongoing [7]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.